Indivior Pharmaceuticals (INDV) Other financing activities (2024 - 2026)
Indivior Pharmaceuticals' (INDV) quarterly Other financing activities came in at $3.0 million in Q1 2026, up 400.0% quarter-over-quarter from -$1.0 million in Q1 2024.
Indivior Pharmaceuticals (INDV) Other financing activities (2024 - 2026) Analysis & Trends
Indivior Pharmaceuticals' Other financing activities history runs 2 years deep, the most recent figure standing at $3.0 million for Q1 2026.
- On a quarterly basis, Other financing activities changed N/A year-over-year to $3.0 million in Q1 2026; TTM through Mar 2026 was $3.0 million, a N/A change from a year earlier, with the FY2024 full-year figure at -$2.0 million, changed N/A from the prior year.
- Other financing activities rose to $3.0 million in Q1 2026 per INDV's latest filing, from -$1.0 million in the prior quarter.
- Across five years, Other financing activities topped out at $3.0 million in Q1 2026 and bottomed at -$1.0 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Indivior Pharmaceuticals | 1.00 Bn | 829.65 Mn | 277.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.00 Mn |
| Mar 31, 2026 | 3.00 Mn |
| Mar 31, 2024 | -1.00 Mn |
| Mar 31, 2024 | -1.00 Mn |